FRM
CAI icon

Fox Run Management’s Caris Life Sciences CAI Stock Holding History

Fox Run Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$659K Buy
+21,526
New +$483K 0.08% 489

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Sixth Street Partners
Sixth Street Partners Dallas, Texas $485M AUM 12.65% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fox Run Management's CAI Position: Q3 2026 in Review

Fox Run Management opened a new position in Caris Life Sciences (CAI) in Q3 2026: 21,526 shares worth $659K. The stake represents 0.08% of the portfolio and ranks #489 among its holdings.

252 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Fox Run Management held 21,526 shares of Caris Life Sciences worth $659K as of Q3 2026.
  • Caris Life Sciences was a new Fox Run Management position in Q3 2026.
  • Caris Life Sciences made up 0.08% of Fox Run Management's portfolio in Q3 2026, its #489 holding.
  • 252 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.